Sun Pharmaceutical Industries, a leading drug manufacturer, has announced plans to invest $100 million in the current fiscal year to commercialize innovative products, with a focus on strengthening its specialty business. The investment will be used to launch two new products, Unloxcyt and Leqselvi, which are indicated for the treatment of metastatic cutaneous squamous cell carcinoma and severe alopecia areata, respectively.
The company’s specialty sales have shown significant growth, with a 17.1% increase to $1,216 million in FY25, and an 8.6% increase to $295 million in the January-March quarter. Chairman and Managing Director Dilip Shanghvi stated that the company is seeking a partner for the future development and commercialization of MM-II, a product for osteoarthritis pain, and is planning a trial of GL0034 in type 2 diabetes.
Sun Pharma has also agreed to acquire Checkpoint Therapeutics, a company specializing in immunotherapy and targeted oncology, and is awaiting approval from the USFDA. The acquisition is expected to accelerate patient access to Unloxcyt, which has recently received approval from the USFDA.
The company has reported a total sales of ₹5,20,41 crore in FY25 and expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal. The FY26 R&D spend is expected to be 6-8% of sales. Shanghvi stated that the company believes in the potential of its products and is committed to investing in their development and commercialization.
Overall, Sun Pharma’s focus on specialty products and innovative therapies is expected to drive growth and expansion in the coming fiscal year. The company’s investment in new products and acquisitions is expected to strengthen its position in the market and provide access to new treatments for patients. With a strong pipeline of products and a commitment to R&D, Sun Pharma is well-positioned for future growth and success.